Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IVAX Diagnostics

This article was originally published in The Gray Sheet

Executive Summary

Diagnostic reagent, instrumentation and software firm announces Sept. 2 that a group of purchasers controlled by industry entrepreneurs Paul Kennedy and Patrice Debregeas have purchased the approximately 72% of Ivax shares owned by Teva Pharmaceutical Industries for $14 million, or $0.70 per share. Kennedy and Debregeas will join Ivax's board of directors and Kennedy is expected to lead the firm's executive management team. Kennedy and Debregeas plan to expand the menu of test kits that Ivax offers in the U.S. and Italy to include other infectious diseases and autoimmune testing sectors
Advertisement

Related Content

Business News In Brief
Advertisement
UsernamePublicRestriction

Register

MT026540

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel